ClinicalTrials.Veeva

Menu

Assessment of Neuropsychiatric Function in Patients With Interstitial Lung Disease

A

Assiut University

Status

Completed

Conditions

Lung Diseases, Interstitial

Study type

Observational

Funder types

Other

Identifiers

NCT05719233
Neuropsychiatric Sequel of ILD

Details and patient eligibility

About

Research on the impact of lung diseases on neuropsychological functioning has revealed impaired cognitive processing in patients with a variety of pulmonary disorders. While the mechanisms responsible for the association of pulmonary diseases and neurocognitive functioning remain unclear, some researchers have attributed it to reduced oxygenation of the brain. Early detection and accurate management of comorbidity have benefits in reducing ILD morbidity and mortality.

Full description

Research on the impact of lung diseases on neuropsychological functioning has revealed impaired cognitive processing in patients with a variety of pulmonary disorders. While the mechanisms responsible for the association of pulmonary diseases and neurocognitive functioning remain unclear, some researchers have attributed it to reduced oxygenation of the brain.

Interstitial Lung Disease (ILD) is an "umbrella" term as it comprises a variety of pulmonary diseases which affect the interstitium (the tissue and space around the air sacs of the lungs). It may be caused by a variety of factors (namely, inhaled substances, medications, infection, connective tissue disease, malignancy or idiopathic reasons) and has a clear negative impact on patients' quality of life, leading to symptoms such as fatigue, dyspnea and coughing. Physical sequelae include reduced lung volumes due to tissue thickening, sometimes caused by inflammation. A further consequence is reduced breathing efficiency, resulting in reduced blood oxygen levels and compromised exercise capacity.

Additionally, the fibrosis of the parenchyma impedes the level of gas exchange. A number of studies have reported mood effects in ILD, suggesting, however, that the diagnosis of depression may be obscured, due to the fatigue and apathy that is often a consequence of ILD.

Early detection and accurate management of Neuropsychiatric comorbidities have benefits in reducing ILD morbidity and mortality.

Enrollment

60 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Interstitial lung disease patients diagnosed using high resolution computed tomography to confirm the diagnosis

Exclusion criteria

  • Patients who refuse to participate in the study.
  • Age less than 18,
  • A history of neurological and/or developmental disorders and related drug treatment,
  • A head injury with loss of consciousness,
  • Active alcohol or drug abuse or a history of abuse prior to testing,
  • A history of any psychiatric disorder or treatment, neurological disorders, psychological disorders, dementia, Alzheimer's disease, end-organ failure conditions

Trial design

60 participants in 2 patient groups

Interstitial Lung disease Group
Description:
Mini-mental state examination (MMSE) Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale Nerve conduction studies High resolution Chest Computed tomography Pulmonary function Test
Control Group
Description:
Mini-mental state examination (MMSE) Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale Nerve conduction studies

Trial contacts and locations

1

Loading...

Central trial contact

Ahmed mohammad abdo Kheder shaddad, lecturer; Waleed Gamal Elddin Khaleel, Lecturer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems